睿知中国医院研究地图
候选清单

正在招募胶质瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor

ClinicalTrials.gov 上登记的一项胶质瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07243340,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.

    入选标准第 2 条

    Developed ≥Grade 3 irAE during previous immunotherapy

    排除标准第 18 条

  3. Karnofsky Performance Status (KPS) ≥ 60%

    入选标准第 6 条

  4. Other malignant tumor within 5 years.

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07243340,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Confirmed recurrent malignant high-grade (WHO grade 3-4) glioma who have received standard therapy and no available treatment.
  3. Measurable lesions exist in accordance with RANO criteria.
  4. Sufficient space for ≥1 mL drug infused into tumor cavity post resection.
  5. Ommaya reservoir has been placed in the operation area, and drug administration conditions are available.
  6. Karnofsky Performance Status (KPS) ≥ 60%
  7. Life expectancy > 12 weeks.
  8. No severe hematological, cardiovascular, liver or kidney diseases.
  9. If the patient is a sexually active female of childbearing potential or if the patient is a sexually active male whose partner is a female of childbearing potential, the patient must use appropriate contraceptive measures for the duration of the treatment and for 6 months afterwards. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days of before the C5252 infusion.
  10. Capable of understanding and complying with protocol requirements.

排除标准:Exclusion Criteria:

  1. Inability to undergo MRI examination for any reason.
  2. Active hemorrhage observed before enrollment.
  3. Imaging test: a. lesion located in non-cerebral regions; b. there are other lesions outside target tumor cavity; c. extra-cranial metastasis.
  4. Tumor lesion locates in ventricular system or there is a clear perforation between the tumor cavity and the ventricle after tumor resection.
  5. History of encephalitis, multiple sclerosis or other central nervous system infections
  6. Treated with steroid hormones and/or more than 5 mg dexamethasone per day or other immunosuppressive drugs for systemic treatment within 4 weeks.
  7. Persistent or active infection, and cannot be controlled by treatment.
  8. Subjects with bleeding tendency or need to take anticoagulant drugs, antiplatelet drugs or non-steroidal anti-inflammatory drugs (NSAIDs) and are unable to discontinue.
  9. Uncontrolled disease, including but not limited to symptomatic congestive heart failure, unstable angina pectoris.
  10. Other malignant tumor within 5 years.
  11. Patients who require an attenuated or live vaccine within 28 days prior to the first trial drug administration and during the study treatment period.
  12. In the period of recurrent herpes simplex virus infection, with corresponding clinical manifestations.
  13. Systemic use (other than topical) of anti-HSV drugs
  14. Prior treatment with any oncolytic virus, cell therapy or gene therapy.
  15. Participants have a history of splenectomy, organ transplantation, bone marrow transplantation or stem cell transplantation
  16. Prior antitumor treatment with intracranial implants, such as Carmustine.
  17. Previous history of allergic reactions to similar biological components such as HSV-1, IL-12 or anti-PD-1 antibodies, or with known allergic reactions to any component of the C5252 prescription, including glycerol.
  18. Developed ≥Grade 3 irAE during previous immunotherapy
  19. History of frequent drug use (including "recreational use") or drug abuse (including alcohol abuse) within one year prior to signing the informed consent form.
  20. Other situation that PI consider subjects not appropriate to participate in the study.

引自 ClinicalTrials.gov, NCT07243340, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07243340,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07243340